AVXL (STOCKS)
Anavex Life Sciences
$3.890000
-0.070000 (-1.77%)
Prev close: $3.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Christopher U. Missling
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $360.03M
- Employees
- 2
- P/E (TTM)
- -8.35
- P/B (TTM)
- 2.90
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $4.36M |
| Benefits Costs and Expenses | $51.06M |
| Costs And Expenses | $43.93M |
| Nonoperating Income/Loss | $4.67M |
| Operating Expenses | $44.60M |
| Selling, General, and Administrative Expenses | $12.80M |
| Research and Development | $31.80M |
| Operating Income/Loss | -$44.60M |
| Income/Loss From Continuing Operations After Tax | -$39.95M |
| Income/Loss From Continuing Operations Before Tax | -$46.69M |
| Interest Income/Expense After Provision For Losses | $4.36M |
| Interest Income/Expense Operating, Net | $4.36M |
| Net Income/Loss | -$39.95M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$39.95M |
| Net Income/Loss Available To Common Stockholders, Basic | -$39.95M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Provision For Loan, Lease, And Other Losses | $0.00 |
| Basic Earnings Per Share | -$0.46 |
| Diluted Earnings Per Share | -$0.46 |
| Basic Average Shares | 259,687,466 |
| Diluted Average Shares | 259,687,466 |
| Assets | $132.99M |
| Current Assets | $132.99M |
| Noncurrent Assets | $0.00 |
| Liabilities | $6.37M |
| Current Liabilities | $6.37M |
| Accounts Payable | $2.64M |
| Other Current Liabilities | $3.73M |
| Noncurrent Liabilities | $0.00 |
| Equity | $126.62M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $126.62M |
| Liabilities And Equity | $132.99M |
| Net Cash Flow From Operating Activities | -$34.08M |
| Net Cash Flow From Operating Activities, Continuing | -$34.08M |
| Net Cash Flow From Investing Activities | -$10.97M |
| Net Cash Flow From Investing Activities, Continuing | -$10.97M |
| Net Cash Flow From Financing Activities | $45.05M |
| Net Cash Flow From Financing Activities, Continuing | $45.05M |
| Net Cash Flow | $0.00 |
| Net Cash Flow, Continuing | $0.00 |
| Comprehensive Income/Loss | -$39.95M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$39.95M |
| Other Comprehensive Income/Loss | $0.00 |